Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Nuformix Plc ( (GB:NFX) ) has shared an update.
Nuformix PLC has submitted a draft application to the European Medicines Agency for Orphan Drug Designation of its lead asset, NXP002, a potential treatment for Idiopathic Pulmonary Fibrosis. The company is also in discussions with potential partners for an out-licence or option agreement for NXP002, signaling ongoing interest and potential collaborations in the market.
More about Nuformix Plc
Nuformix is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company leverages its expertise in discovering, developing, and patenting novel drug forms with improved physical properties to create new products for new indications, thereby generating attractive commercial opportunities. Nuformix has a pipeline of preclinical assets poised for significant value and early licensing potential.
YTD Price Performance: 20.0%
Average Trading Volume: 27,649,915
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £851.6K
For detailed information about NFX stock, go to TipRanks’ Stock Analysis page.
